Clinical trial
Caduet in an Untreated Subject Population
NCT00332761 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00332761 |
|---|---|
| Title | Caduet in an Untreated Subject Population |
| Official title | An 8-Week Randomized, Double-Blind, Placebo-Controlled Trial Examining The Efficacy And Safety Of Caduet® In Simultaneously Achieving Blood Pressure And Lipid Goals In An Untreated Hypertensive And Dyslipidemic Subject Population. (CUSP - Caduet in Untreated Subject Population) |
| Acronym | CUSP |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hypertension, Dyslipidemia |
| Intervention type | Drug |
| Interventions | Caduet |
| Enrollment | 220 |
| Start date | Jun 1, 2006 |
| Completion | Sep 1, 2007 |
| First posted | Jun 2, 2006 |
| Last update posted | Jan 27, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: